These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22826453)

  • 21. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 22. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
    Engel SS; Williams-Herman DE; Golm GT; Clay RJ; Machotka SV; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2010 Jun; 64(7):984-90. PubMed ID: 20412332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
    Stafford S; Elahi D; Meneilly GS
    J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
    Sin C; Mahé E; Sigal ML
    Diabetes Metab; 2012 Dec; 38(6):571-3. PubMed ID: 23183246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
    Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.
    Furukawa S; Kumagi T; Miyake T; Ueda T; Niiya T; Nishino K; Murakami S; Murakami M; Matsuura B; Onji M
    Endocr J; 2012; 59(4):329-33. PubMed ID: 22277726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
    MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
    [No Abstract]   [Full Text] [Related]  

  • 28. More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods.
    Buiu C; Avram S; Duda-Seiman D; Milac AL; Duda-Seiman C; Pacureanu L; Borcan F
    Curr Comput Aided Drug Des; 2014; 10(3):237-49. PubMed ID: 25756669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
    Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 32. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
    Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
    Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.
    Neumiller JJ; Odegard PS; White JR; Setter SM; Campbell RK
    Diabetes Educ; 2008; 34(2):183-200. PubMed ID: 18375772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Chwieduk CM
    Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
    Yuan G; Jia J; Zhang C; Yu S; Dong S; Ye J; Zhu T; Tang B; Qian W; Wang D; Yang L; Zhou L; Mao C
    Endocr J; 2014; 61(5):513-21. PubMed ID: 24621778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
    Saito T; Ohnuma K; Suzuki H; Dang NH; Hatano R; Ninomiya H; Morimoto C
    Diabetes Res Clin Pract; 2013 Oct; 102(1):e8-e12. PubMed ID: 23937822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease: The case of sitagliptin].
    Seguí Díaz M
    Semergen; 2016; 42(5):329-30. PubMed ID: 26524980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.